Literature DB >> 8005535

Internalization of human extracellular-superoxide dismutase by bovine aortic endothelial cells.

H Ohta1, T Adachi, K Hirano.   

Abstract

The high heparin-affinity subtype C of the secretory enzyme extracellular-superoxide dismutase (EC-SOD) mainly exists on the outside of endothelial cell surface in the vasculature. Radioiodinated recombinant EC-SOD C(r-EC-SOD C) bound to cultured bovine aortic endothelial cells (BAE cells) at 4 degrees C with an association constant of 9.35 x 10(6) M-1 and maximum binding of 600 ng/dish (3109 ng/mg cellular protein). When incubated at 37 degrees C for 1 h, some 125I-r-EC-SOD C was no longer releasable by heparin treatment, suggesting that 125I-r-EC-SOD C was internalized by BAE cells. Since the internalization was inhibited in the presence of heparin in medium, this step was mediated by the binding to cell surface heparin sulfate proteoglycans. When cells containing internalized 125I-r-EC-SOD C were incubated in newly added medium at 37 degrees C for up to 1 h, 54% of radioactivity was recovered in new medium. However, 71% of the radioactive materials released to the medium, presumably 125I-r-EC-SOD C and its metabolic products, had lost heparin binding activity. Much of internalized 125I-r-EC-SOD C was degraded to low molecular weight peptides, because 54% of the radioactive products released to the medium were trichloroacetic acid-soluble and 59% of them were below 10 kDa. About one-fourth of radioactive materials were recycled 125I-r-EC-SOD judged from heparin-HPLC and Sephacryl S-200 column chromatography. In the presence of chloroquine, lysosomal protease inhibitor, the release of internalized 125I-r-EC-SOD C decreased to 59% compared with the control culture.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8005535     DOI: 10.1016/0891-5849(94)90128-7

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  7 in total

1.  Deficiency of lung antioxidants in idiopathic pulmonary arterial hypertension.

Authors:  Fares A Masri; Suzy A A Comhair; Iva Dostanic-Larson; Francisco Takao Kaneko; Raed A Dweik; Alejandro C Arroliga; Serpil C Erzurum
Journal:  Clin Transl Sci       Date:  2008-09       Impact factor: 4.689

Review 2.  Superoxide dismutases: role in redox signaling, vascular function, and diseases.

Authors:  Tohru Fukai; Masuko Ushio-Fukai
Journal:  Antioxid Redox Signal       Date:  2011-06-06       Impact factor: 8.401

3.  Overexpression of extracellular superoxide dismutase attenuates heparanase expression and inhibits breast carcinoma cell growth and invasion.

Authors:  Melissa L T Teoh; Matthew P Fitzgerald; Larry W Oberley; Frederick E Domann
Journal:  Cancer Res       Date:  2009-07-14       Impact factor: 12.701

4.  Rational design of a secreted enzymatically inactive mutant of extracellular superoxide dismutase.

Authors:  Adam J Case; James J Mezhir; Brianne R O'Leary; Jennifer E Hrabe; Frederick E Domann
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

5.  Substitution of glycine for arginine-213 in extracellular-superoxide dismutase impairs affinity for heparin and endothelial cell surface.

Authors:  T Adachi; H Yamada; Y Yamada; N Morihara; N Yamazaki; T Murakami; A Futenma; K Kato; K Hirano
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

6.  Cloning, Purification, and Characterization of Recombinant Human Extracellular Superoxide Dismutase in SF9 Insect Cells.

Authors:  Pravesh Shrestha; Ji-Hye Yun; Woo Taek Kim; Tae-Yoon Kim; Weontae Lee
Journal:  Mol Cells       Date:  2016-02-25       Impact factor: 5.034

Review 7.  Role of oxidative stress in refractory epilepsy: evidence in patients and experimental models.

Authors:  Noemi Cardenas-Rodriguez; Bernardino Huerta-Gertrudis; Liliana Rivera-Espinosa; Hortencia Montesinos-Correa; Cindy Bandala; Liliana Carmona-Aparicio; Elvia Coballase-Urrutia
Journal:  Int J Mol Sci       Date:  2013-01-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.